Observe Medical (OBSRV) Q2 2024 earnings summary

Executive summary

• H1 2024 operating revenues reached NOK 13.1 million, up 10% year-over-year, driven by UnoMeter sales and global distribution expansion.

• Gross profit increased to NOK 5.0 million, with gross margin at 38.2%, up 2 percentage points from last year.

• Management changes included a new CEO and CFO to drive commercial and financial transformation.

• Strategic shift in ultrasound segment with a signed LOI with a U.S. imaging company and Biim-Fresenius agreement extension.

• Nordic distribution was divested to Vingmed, focusing resources on international growth and product innovation.

Financial highlights

• H1 2024 revenue reached NOK 13.1 million, up from NOK 11.8 million in H1 2023.

• Gross profit was NOK 5.0 million, with a gross margin of 38.2%.

• EBITDA before non-recurring items was negative NOK 12.6 million, improved from negative NOK 19.4 million last year.

• Net loss for H1 2024 was negative NOK 22.5 million, improved from NOK 35.2 million in H1 2023.

• Cash position at June 30, 2024, was NOK 2.7 million, supported by a NOK 22 million private placement.

Outlook and guidance

• Full launch of UnoMeter Safeti Plus expected in late September/early October 2024, anticipated to drive significant revenue and profitability.

• Revenue guidance for 2025 is NOK 100–135 million, with new product launches and distribution business contributing.

• Medium-term outlook anticipates diversified revenue streams and further gross margin improvement from differentiated products.

• Organizational growth and innovation planned to support strong revenue growth and global expansion.

• Focus on completing Biim due diligence, preparing for 2025 launch of UnoMeter Safeti Max, and managing logistical complexity.